Johnson & Johnson's Centocorntho Biotechnology Company announced yesterday，The acquisition of respivert pharmaceutical has been completed。The latter is a main R & D and use of small molecules、Pharmaceutical Company that inhale therapy Stake Sports Bettingto treat lung disease。 
    Through this acquisition，Centocorortho Biotechnology Company will get small molecules for severe lung diseases，Advanced technology of inhaling therapy。Details of the two parties have not disclosed the transaction details，But Centocorntho supplementation，Respivert will continue to maintain an independent status of research and development at Empire University of London。